Engineering next-generation CAR-T cell therapy for cancer

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Engineering next-generation CAR-T cell therapy for cancer

This was a live-only webinar that ran on August 21st, with no on demand access available.

The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has demonstrated robust efficacy in the treatment of advanced hematological malignancies. However, challenges such as antigen escape and immunosuppression limit the long-term efficacy of adoptive T cell therapy, particularly for solid tumors.

This webinar will discuss the development of next-generation T cells that can target multiple cancer antigens, modify the tumor microenvironment, and/or engage endogenous immunity to overcome tumor defense mechanisms.

This presentation will highlight the potential of synthetic biology in generating novel mammalian cell systems with multifunctional outputs for therapeutic applications.

Attend this webinar to learn more about:

Current obstacles to achieving safe and efficacious tumor control with CAR-T cell therapy
Strategies to overcome current limitations of CAR-T cell therapy for oncology applications
Using synthetic biology to develop improved T cell therapies for cancer

Yvonne Chen

Professor of Microbiology, Immunology, and Molecular Genetics at UCLA

Dr Yvonne Chen is a Professor of Microbiology, Immunology, and Molecular Genetics at UCLA. She received her B.S. and PhD in chemical engineering from Stanford University and the California Institute of Technology, respectively, and was a junior fellow in the Harvard Society of Fellows.

The Chen Laboratory applies biomolecular engineering to the development of novel mammalian-cell systems for clinical use and led the first investigator-initiated clinical trial on CAR T cell therapy at UCLA. The Chen Lab has been recognized by the NIH Director’s Early Independence Award, the NSF CAREER Award, and the Cancer Research Institute Lloyd J. Old STAR Program, among others.